Last reviewed · How we verify
Bromanautine (bromazine)
At a glance
| Generic name | bromazine |
|---|---|
| Sponsor | Allergan/AbbVie |
| Drug class | bromazine |
| Target | Histamine H1 receptor |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Common cold
- Cough
- Nasal congestion
- Nasal discharge
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromanautine CI brief — competitive landscape report
- Bromanautine updates RSS · CI watch RSS
- Allergan/AbbVie portfolio CI